- Home
- NNI vs AKRO Comparison
NNI vs AKRO Comparison
Compare NNI & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNI
- AKRO
- Stock Information
- Founded
- NNI 1978
- AKRO 2017
- Country
- NNI United States
- AKRO United States
- Employees
- NNI N/A
- AKRO N/A
- Industry
- NNI Finance: Consumer Services
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- NNI Finance
- AKRO Health Care
- Exchange
- NNI Nasdaq
- AKRO Nasdaq
- Market Cap
- NNI 4.2B
- AKRO 3.9B
- IPO Year
- NNI 2003
- AKRO 2019
- Fundamental
- Price
- NNI $116.14
- AKRO $49.65
- Analyst Decision
- NNI Hold
- AKRO Strong Buy
- Analyst Count
- NNI 1
- AKRO 8
- Target Price
- NNI $98.00
- AKRO $82.50
- AVG Volume (30 Days)
- NNI 76.4K
- AKRO 1.9M
- Earning Date
- NNI 05-08-2025
- AKRO 05-12-2025
- Dividend Yield
- NNI 0.96%
- AKRO N/A
- EPS Growth
- NNI 44.75
- AKRO N/A
- EPS
- NNI 5.30
- AKRO N/A
- Revenue
- NNI $1,365,360,000.00
- AKRO N/A
- Revenue This Year
- NNI $15.13
- AKRO N/A
- Revenue Next Year
- NNI $5.32
- AKRO N/A
- P/E Ratio
- NNI $21.93
- AKRO N/A
- Revenue Growth
- NNI 9.48
- AKRO N/A
- 52 Week Low
- NNI $97.13
- AKRO $17.86
- 52 Week High
- NNI $127.32
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- NNI 57.33
- AKRO 63.34
- Support Level
- NNI $111.82
- AKRO $44.94
- Resistance Level
- NNI $117.42
- AKRO $49.29
- Average True Range (ATR)
- NNI 2.19
- AKRO 3.33
- MACD
- NNI -0.04
- AKRO 0.67
- Stochastic Oscillator
- NNI 52.75
- AKRO 86.02
About NNI Nelnet Inc.
Nelnet Inc is a United States based company engaged in these four reportable segments; Loan Servicing and Systems focuses on student and consumer loan origination services and servicing, loan origination and servicing-related technology solutions, and outsourcing business services; Education Technology Services and Payments segment provides education services, payment technology, and community management solutions for K-12 schools, institutions, churches, and businesses; Asset Generation and Management segment includes the acquisition and management of student and other loan assets; and Nelnet Bank focuses on the private education and unsecured consumer loan markets. Maximum revenue for the company is generated from its Education Technology Services and Payments segment.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.